• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

FDA Approves Enzyme Replacement Therapy for Rare Clotting Disorder


Adzynma is a recombinant protein designed to replace the deficient ADAMTS13 enzyme.

The FDA has approved Takeda’s Adzynma (ADAMTS13, recombinant-krhn) to treat adults and children with congenital thrombotic thrombocytopenic purpura (cTTP).

cTTP is an ultra-rare, chronic blood clotting disorder caused by a deficiency in the ADAMTS13 enzyme. In TTP, blood clots form in small blood vessels, limiting the flow of blood to the brain, kidneys, and heart. When left untreated, acute TTP events have a mortality rate of more than 90%.

Adzynma is a therapy that replaces the deficient ADAMTS13 enzyme. It is expected to be available in December, and a price will be available at that time.

“In recent decades, significant progress has been made to better understand the link between ADAMTS13 deficiency and cTTP, ultimately leading to this moment where we finally have an FDA-approved treatment option for patients living with this rare disease,” Spero R. Cataland, M.D., professor of internal medicine at the Wexner Medical Center at The Ohio State University, co-director at the U.S. Thrombotic Microangiopathy Alliance (USTMA) and Adzynma clinical trial investigator, said in a press release.

The FDA approval was supported by the totality of the evidence provided by the analysis of efficacy, pharmacokinetic, safety and tolerability data from a phase 3 trial that enrolled 37 patients who received the enzyme therapy, as well as by data from the continuation trial. In the phase 3 trial, no patient treated with Adzynma experienced an acute TTP event.

The most common adverse reactions were headache, diarrhea, migraine, abdominal pain, nausea, upper respiratory tract infection, dizziness and vomiting.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.